DIA 2018

The nexus of innovation, policy improvements changing at never-before-seen pace: DIA

By Melissa Fassbender contact

- Last updated on GMT

Related tags: DIA, Innovation, Regulation, Policy, Drug discovery, Market access

Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.

Early patient engagement, regulatory science, translational medicine, and sustainable access to medicines were among the key topics of this year’s DIA 2018 Global Annual Meeting.

To learn more, we sat down with Barbara Lopez Kunz, chief global executive, DIA, at the meeting, which took place June 24-28 in Boston, MA.

“We’re at a really interesting time in health care,”​ said Lopez Kunz, “where the nexus of innovation and the nexus of regulatory policy improvements is changing at a pace that we haven’t seen before.”

With this foundation, Lopez Kunz said DIA has become even more relevant, as discussions expand from early discovery to post-license issues, including sustainable access to medicines – the “big topic”​ on everybody’s mind.

She also noted the importance of having not only good science, “but good collaboration around the world … Because there is no need to reinvent the wheel.”

However, the industry continues to face criticism over its failure rate, with nearly nine out of 10 drugs failing before making it to market​.

“The fact is, you have to learn and you have to better understand the biology to be able to design those new therapies,”​ said Lopez Kunz.

“Every increment of knowledge leads you to an every increasing understanding around how to target and how to design the right kinds of therapies … And unlike other parts of our world, other industries, as you learn more, the predecessor discoveries are no longer relevant.”

As such, pharmaceuticals do not have a product lifecycle in which the previous version continues to be a “commercially viable entity,”​ she explained.

“So this is a real issue, and it’s all wrapped up in the problem around cost and sustainability.”

To hear Kunz Lopez discuss more these topics in further detail, watch the full interview in the video above.

Related news

Show more

Related products

show more

Keys To A Successful Rapid Commercial Launch

Keys To A Successful Rapid Commercial Launch

Catalent Pharma Solutions | 21-Oct-2020 | Insight Guide

Pharma and biotech companies are dedicating resources to new treatments with the hope of helping patients. The quicker they can get products to patients,...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us

Products

View more

Webinars